A recent study from the from the Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States of America shows that “High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.“ This study was published in the 8 Feb’13 issue of the Journal Molecular Medicine by Drs. Bauer PM, Bauer EM and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary hypertension: Cirsilol (3′,4′,5-trihydroxy-6,7-dimethoxyflavone), a flavone isolated from Achillea fragrantissima, suppresses pulmonary hypertension via up regulation of its target gene. This study suggests, for the first time, that Cirsilol, by decreasing the expression of its target gene, may: (1) decrease Right ventricular systolic pressure, and (2) inhibit thickening of the pulmonary artery wall. Together, pharmacological formulations encompassing “Cirsilol or its analogues“ may be used to treat patients suffering from pulmonary hypertension.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for pulmonary hypertension: Cirsilol (3′,4′,5-trihydroxy-6,7-dimethoxyflavone), a flavone isolated from Achillea fragrantissima, suppresses pulmonary hypertension via up regulation of its target gene, 4/March/2015, 08.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Cirsilol stifles pulmonary hypertension
Amount: $500*